GlassScriptPhysician profile
Alyssa R Everson
NPI 1093335796
$1,173.57
in general payments reported to CMS, 2019-2025
29 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $101 · 2023: $136 · 2024: $420 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $106.60 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $94.51 | 2021-2024 | Nuplazid |
| Ucb, INC. | $92.77 | 2024-2025 | Briviact, Rystiggo, Nayzilam |
| Argenx US, INC. | $65.17 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $63.01 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Amneal Pharmaceuticals LLC | $61.26 | 2023-2025 | Rytary, Crexont |
| Axsome Therapeutics, INC. | $59.08 | 2024-2025 | Symbravo, Sunosi |
| Lundbeck LLC | $58.25 | 2021-2024 | Rexulti |
| Abbvie INC. | $49.43 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $46.79 | 2023-2025 | Ultomiris |
| Emd Serono, INC. | $40.52 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $39.18 | 2021-2025 | |
| Ns Pharma, INC. | $38.70 | 2025 | Viltepso |
| Lilly USA, LLC | $36.78 | 2023-2024 | Reyvow, Emgality |
| Celgene Corporation | $35.08 | 2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $32.65 | 2022 | |
| Kyowa Kirin, INC. | $28.98 | 2024 | Nourianz |
| Neurelis, INC. | $21.73 | 2025 | Valtoco |
| Nevro Corp. | $21.45 | 2022 | |
| Pfizer INC. | $20.92 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.71 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $20.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.61 | 2025 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $18.85 | 2024 | Lumryz |
| Philips North America LLC | $17.34 | 2025 | Event |
| Teva Pharmaceuticals USA, INC. | $16.91 | 2024 | Austedo Xr |
| Tg Therapeutics, INC. | $16.74 | 2024 | |
| Csl Behring | $16.55 | 2024 | Hizentra |
| Hospira, INC. | $14.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Everson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.